论文部分内容阅读
AIM: To describe the en bloc perfluorodissection(EBPD) technique and to demonstrate the applicabilityof using preoperative intravitreal bevacizumab duringsmall-gauge vitreoretinal surgery(23-gauge transconjunctival sutureless vitrectomy) in eyes with advancedproliferative diabetic retinopathy(PDR) with tractionalretinal detachment(TRD).METHODS: This is a prospective, interventional caseseries. Participants included 114(eyes) with advancedproliferative diabetic retinopathy and TRD. EBPD wasperformed in 114 eyes(consecutive patients) during23-gauge vitrectomy with the utilization of preoperativebevacizumab(1.25 mg/-0.05 mL). Patients mean age was 45 years(range, 21-85 years). Surgical time had a mean of 55 min(Range, 25-85 min). Mean follow up of this group of patients was 24 mo(range, 12-32 mo). Main outcome measures included best-corrected visual acuity(BCVA), retinal reattachment, and complications.RESULTS: Anatomic success occurred in 100%(114/-114) of eyes. Significant visual improvement [≥ 2 Early Treatment Diabetic Retinopathy Study(ETDRS) lines] was obtained in 69.2%(79/-114), in 26 eyes(22.8%) BCVA remained stable, and in 8 eyes(7%) BCVA decreased(≥ 2 ETDRS lines). Final BCVA was 20/-50 or better in 24% of eyes, between 20/-60 and 20/-400 in 46% of eyes, and worse than 20/-400 in 30% of eyes. Complications included cataract in 32(28%) eyes, iatrogenic retinal breaks in 9(7.8%) eyes, vitreous hemorrhage requiring another procedure in 7(6.1%) eyes, and phthisis bulbi in 1(0.9%) eye.CONCLUSION: This study demonstrates the usefulne-ss of using preoperative intravitreal bevacizumab and EBPD during smallgauge vitreoretinal surgery in eyes with TRD in PDR.
AIM: To describe the en bloc perfluorodissection (EBPD) technique and demonstrates the applicability of using preoperative intravitreal bevacizumab duringsmall-gauge vitreoretinal surgery (23-gauge transconjunctival sutureless vitrectomy) in eyes with advanced photoliferative diabetic retinopathy (PDR) with tractional detachment detachment (TRD). METHODS: This is a prospective, interventional case series. 114 participants (eyes) with advancedproliferative diabetic retinopathy and TRD. EBPD wasperformed in 114 eyes (consecutive patients) during23-gauge vitrectomy with the utilization of preoperative bevacizumab (1.25 mg / -0.05 mL). Surgical time had a mean of 55 min (Range, 25-85 min). Mean follow up of this group of patients was 24 months (range, 12-32 months) ). Main event measures included best-corrected visual acuity (BCVA), retinal reattachment, and complications. Significant visual improvs in 100% (114 / -114) of eyes. ement [≥ 2 Early Treatment Diabetic Retinopathy Study (ETDRS) lines] was obtained in 69.2% (79 / -114) in 26 eyes (22.8%) BCVA remained stable, and in 8 eyes (7%) BCVA decreased ETDRS lines). Final BCVA was 20 / -50 or better in 24% of eyes, between 20 / -60 and 20 / -400 in 46% of eyes, and worse than 20/400 in 30% of eyes. eye, iatrogenic retinal breaks in 9 (7.8%) eyes, vitreous hemorrhage requiring another procedure in 7 (6.1%) eyes, and phthisis bulbi in 1 (0.9%) eye.CONCLUSION: This study demonstrates the usefulne-ss of using preoperative intravitreal bevacizumab and EBPD during smallgauge vitreoretinal surgery in eyes with TRD in PDR.